Morgan Stanley Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target decreased by investment analysts at Morgan Stanley from $1,235.00 to $1,184.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price indicates a potential upside of 40.45% from the company’s previous close.

A number of other equities analysts have also recently commented on REGN. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, Barclays cut their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,090.24.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $4.83 during mid-day trading on Friday, hitting $843.03. 668,986 shares of the stock were exchanged, compared to its average volume of 515,671. The stock’s fifty day simple moving average is $1,065.54 and its two-hundred day simple moving average is $1,039.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals has a 12-month low of $783.57 and a 12-month high of $1,211.20. The stock has a market capitalization of $92.94 billion, a price-to-earnings ratio of 22.20, a P/E/G ratio of 3.17 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.79 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals will post 37.46 EPS for the current year.

Insider Buying and Selling

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $26,000. Sachetta LLC lifted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter worth $28,000. Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $33,000. Finally, Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $33,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.